CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 320 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818168
NCT00818168N/ACompleted
CompareCT.gov

Remicade Safety Line (Ankylosing Spondylitis)

Merck Sharp & Dohme LLC·observational·Posted Jan 7, 2009·Updated Sep 3, 2015

In Brief

An observational study evaluating Infliximab for Spondylitis, Ankylosing. Completed, enrolled 320 participants.

Detailed Summary

This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylitis, Ankylosing
Countries--
CollaboratorsCentocor, Inc.

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2009
Enrollment StartJul 1, 2003
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 17.5 years ago

Interventions

Infliximabbiological

Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)